Aerska raises $39 million Series A for brain-delivered RNA medicines
EQT Dementia Fund and age1 co-led the financing, with participation from Iaso Ventures and existing investors.
Aerska announced a $39 million Series A on February 9, 2026, to advance its brain shuttle platform for RNA medicines.
The proceeds will support its antibody-oligo conjugate platform as it progresses toward clinical development for neurological diseases. The financing also adds representatives from EQT and age1 to the board.
Use of funds
Develop brain shuttle RNA delivery platform
Advance neurological disease programmes toward clinical development